A study in Diabetes Care found that verapamil, a calcium channel blocker for heart conditions, is linked to a 23% lower risk of type 2 diabetes compared to other CCBs. Involving over 90,000 adults, the study suggests verapamil may offer metabolic benefits and help prevent diabetes in at-risk individuals.